Particularly attention was given to GSK343, a competitive inhibitor of methionine histone lysine methyltransferase EZH2 [24,25,26]; it has been reported that GSK343 powerfully inhibits EZH2 activity, suppressing the progression of various cancer types including ovarian cancer [27], osteosarcoma [28] neuroblastoma and glioma [26], promoting programmed cell death and autophagy processes [29]. This evidence concerns the gene EZH2 and neuroblastoma.